UK-based CBD Science Group has received an endorsement from the National Cancer Research Institute (NCRI) for its study investigating the role of cannabis in treating cancer pain.
Biopharmaceutical company CBD Science Group has received an endorsement from the NCRI, which has seen its NCRI Living With and Beyond Cancer (LWBC) Executive Group endorse CBD Science’s Real World Evidence (RWE) study into the role that cannabinoids can play in treating cancer-related pain.
There are currently an estimated three million patients in the UK suffering from cancer, 39.3% of which are affected by pain following curative treatment; 55% affected by pain during anticancer treatment; and 66.4% in advanced, metastatic, or terminal disease.
An alternative treatment for pain
CBD Science Group is carrying out the peer-reviewed clinical trial which aims to deliver approved therapies to patients nationally at a rapid pace.
CCO of CBD Science, Graeme McFarlane, said: “We are delighted and proud to have been offered this endorsement from the NCRI LWBC, which offers hope to millions of people with long term cancer pain around the world.
“This partnership will further progress CBD Science Group towards our objective of realising the advantages of cannabinoids in fulfilling this urgent need of suffering patients. We strongly believe in the opportunity that our RWE study presents, and look forward to working closely and deepening our relationship with the NCRI.”
The NICE guidelines for medical cannabis found that evidence is lacking for chronic pain associated with cancer patients, which CBD Science says renders research into the use of cannabinoids as an alternative medicine timely.
Read more: Breast cancer breakthrough for medical cannabis company Appollon Formularies
Co-chair of NCRI Living With and Beyond Cancer Research Group, professor Emeritus Sam Ahmedzai, commented: “Previous research into cancer-related pain focused on those with advanced disease, however, there is a large and rapidly growing population of people surviving for many years with cancer.
“The reality is that chronic pain related to the cancer itself or indeed arising from the anti-cancer treatments, is an insurmountable barrier to living a productive and rewarding life with family and friends – at all stages of cancer.
“Sadly current pain treatment options are largely ineffective or cause even more harmful side-effects; therefore new research is urgently needed to find better therapies. I am delighted to actively participate in CBD Science Group’s goal of finding an effective and safer medicinal cannabis solution to relieve the suffering of patients living with cancer-related pain.”
[activecampaign form=31]
